TABLE 1.
Characteristics of HIV-infected patients with respect to coreceptor phenotype at the time of treatment interruption
| Characteristica | Overall (n = 53) | Patients with X4 strain (n = 15) | Patients with R5 strain (n = 38) | P value |
|---|---|---|---|---|
| No. (%) of males | 37 (69.8) | 10 (66.7) | 27 (69.8) | 0.7 |
| No. (%) with indicated HIV risk factor | 0.8 | |||
| IVDU | 8 (15.4) | 3 (20.0) | 5 (13.5) | |
| Unprotected sex (heterosexual) | 24 (46.2) | 7 (46.7) | 17 (45.9) | |
| Unprotected sex (homosexual) | 20 (38.5) | 5 (33.3) | 15 (40.5) | |
| Median (IQR) age (yr) | 42 (37-47.5) | 41 (39-44) | 42 (37-48.2) | 0.7 |
| No. (%) at CDC stage A3 or B3 or C | 16 (30.2) | 4 (26.7) | 12 (31.6) | 0.7 |
| Median (IQR) CD4+ T cell count (cells/μl) at nadir | 290 (161-393) | 308 (136-396) | 279 (170-393) | 0.6 |
| Median (IQR) CD4+ T cell count (cells/μl) at baseline | 801 (625-987) | 921 (801-1120) | 711 (588-940) | 0.008 |
| No. (%) with more or less than median CD4+ T cell count (>807 CD4+ T cells/μl) at baseline | 25 (47.2) | 11 (73.3) | 14 (36.8) | 0.03 |
| No. (%) currently receiving indicated therapy | ||||
| NNRTI | 26 (49.1) | 7 (46.7) | 19 (50.0) | 0.8 |
| PI | 19 (35.8) | 7 (46.7) | 12 (31.6) | 0.3 |
| NRTI only | 8 (15.1) | 1 (6.7) | 7 (18.4) | 0.3 |
| Median (IQR) length (mo) of current therapy | 26.5 (11.7-50.2) | 31 (9-53) | 25 (15-47) | 0.9 |
| Median (IQR) total drug exposure (mo) | 84 (62.2-103.2) | 83 (65-104) | 85 (53-102) | 0.9 |
| Median (IQR) amt of HIV DNA at baseline (copies/106 PBMCs) | 330 (146.5-658.5) | 330 (239-551) | 343 (126-668) | 0.8 |
a
IVDU, intravenous drug user; IQR, interquartile range; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.